摘要
抗Xa活性分析首先用于测量血浆中的肝素含量,其检测原理是发色底物法。目前,抗Xa活性分析可以检测能抑制Xa活性的抗凝药物浓度。它通过检测外源添加的活化因子a被普通肝素-抗凝血酶复合体、低分子肝素-抗凝血酶复合体、磺达肝葵钠-抗凝血酶复合体、直接口服抗凝药物的抑制程度,来反映接受相应治疗的药物浓度。本文综述了这些抗凝药物的特征,以及抗Xa活性分析在监测这些抗凝药物治疗中的应用和局限性。
The anti-Xa assay is firstly introduced to measure the concentration of heparin in plasma.The principle of it is chromogenic substrate assay.At present,the anti-Xa assay can measure the concentration of anticoagulants that inhibits factor Xa.To generate the drug concentration,the assay measures the extent to which exogenous factor Xa is inhibited by complexes of unfractionated heparin(UFH)-antithrombin,low molecular weight heparin(LMWH)-antithrombin,fondaparinux-antithrombin or direct oral anticoagulants(DOACs)in patients being treated with UFH,LMWH,fondaparinux or DOACs,respectively.This paper reviews the characteristics of UFH,LMWH,fondaparinux and DOACs,also the utilities and limitations of anti-Xa assay in monitoring therapy with these anticoagulants.
作者
赖宇尧
李桂珊
王志明
张珊
廖守万
LAI Xuyao;LI Guishan;WANG Zhiming;ZHANG Shan;LIAO Shouwan(Clinical Laboratory, Nan′ao People′s Hospital, Shenzhen Dapeng New District, Shenzhen 518121, China)
出处
《标记免疫分析与临床》
CAS
2020年第8期1444-1449,共6页
Labeled Immunoassays and Clinical Medicine
